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Background: Although annual influenza vaccination could decrease the significant economic and humanistic
burden of influenza in the United States, immunization rates are below recommended levels, and concerns remain
whether immunization programs can be cost beneficial. The research objective was to compare cost benefit of
various immunization strategies from employer, employee, and societal perspectives.
Methods: An actuarial model was developed based on the published literature to estimate the costs and benefits
of influenza immunization programs. Useful features of the model included customization by population age and
risk-level, potential pandemic risk, and projection year. Various immunization strategies were modelled for an
average U.S. population of 15,000 persons vaccinated in pharmacies or doctor’s office during the 2011/12 season.
The primary outcome measure reported net cost savings per vaccinated (PV) from the perspective of
various stakeholders.
Results: Given a typical U.S. population, an influenza immunization program will be cost beneficial for employers
when more than 37% of individuals receive vaccine in non-traditional settings such as pharmacies. The baseline
scenario, where 50% of persons would be vaccinated in non-traditional settings, estimated net savings of $6 PV.
Programs that limited to pharmacy setting ($31 PV) or targeted persons with high-risk comorbidities ($83 PV) or
seniors ($107 PV) were found to increase cost benefit. Sensitivity analysis confirmed the scenario-based findings.
Conclusions: Both universal and targeted vaccination programs can be cost beneficial. Proper planning with cost
models can help employers and policy makers develop strategies to improve the impact of immunization programs.
Keywords: Influenza, Immunization, Vaccination, Cost benefit, Economic modelBackground
Seasonal influenza (flu) is a costly disease to patients,
employers, and society in terms of direct and indirect
medical cost and lost productivity. The most recent esti-
mates of the cost of flu from 2003 showed $10.4 billion
annually in direct medical costs and $16.3 billion in in-
direct costs associated with lost earnings and loss of life
[1]. From a societal perspective, the total economic bur-
den of the flu in the United States is $87.1 billion [1].
During influenza season, influenza-like-illness (ILI) is re-
sponsible for 45% of workdays lost and for 49% of low
productivity days among working adults aged 50–64 years
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reproduction in any medium, provided the orAlthough vaccination is effective in decreasing the bur-
den of influenza, immunization rates are below recom-
mended levels [3]. As of the 2010 influenza season, the
Centers for Disease Control and Prevention (CDC)
recommended that everyone 6 months of age and older
should be vaccinated against the flu as soon as a seasonal
vaccine is available [4]. Recent evidence from the Canad-
ian health system asserts that universal vaccination
decreased the burden of ILI [5,6]; however, concerns re-
main in the United States about whether such efforts will
be cost effective and whether there are enough
immunization providers to achieve universal vaccination
[7]. Immunizations were traditionally delivered via three
channels: (a) physicians in their offices, (b) public health
systems in a number of settings such as community
health clinics and schools, and (c) in hospitals [8]. In the
mid-1990’s, national programs were developed to train
pharmacists to provide immunization services [9]. Thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cination in 2010 further highlighted the need for
immunization providers and the value of pharmacy-
based vaccinations.
Vaccination coverage is defined as the percentage of
persons in a population who have received at least one
dose of influenza-containing vaccine in a given year. To
improve vaccine coverage in the United States, a Report
of the National Vaccine Advisory Committee [10] advo-
cated vaccinations in nontraditional settings such as
pharmacies and workplaces. Compared to traditional
channels such as physician offices, nontraditional set-
tings can improve access, increase convenience, and de-
crease cost [8]. Furthermore, the CDC recognizes the
opportunity of collaborating with employers and busi-
nesses to promote vaccination [11]. Employers can re-
duce both access and cost barriers to vaccination by
offering on-site immunization, designing a benefit plan
that minimizes out-of-pocket cost, or providing financial
incentives for community-based immunization.
When businesses wish to evaluate the allocation of
resources, they often build models to aid in decision-
making. Several researchers have published economic
models to evaluate either the cost or benefits of seasonal
influenza vaccination, or both [2,12,13]. No published
model was found which (a) allowed decision makers to
project outcomes for a specific target population, (b)
aggregated different models to account for a wide array
of immunization strategies, (c) allocated savings to mul-
tiple stakeholders, or (d) trended value to the current
year. Therefore, we developed a model that combines
components from the published literature in a flexible
yet comprehensive approach. The actuarial model allows
users to estimate the costs and benefits of any commu-
nity or worksite immunization program. The resulting
value of immunization was evaluated from three per-
spectives: an employee, an employer, and society. When
vaccination prevents influenza, employees may have
reduced expenses, improved quality of life, and possiblyTable 1 Summary of model variables
Inputs Cos
• Projection year • H
• Client population demographics (i.e., age and dependent profile) • O
• Vaccination delivery channel • Se
• Percentage vaccinated • A
• Economic variables (e.g., average value of workday lost) • Pr
• Benefit design (e.g., flu vaccine cost-sharing policy) • D
• Vaccine effectiveness
• Risk Level
• Risk of pandemicreduced wage-loss. If their employees remain healthy,
employers could benefit from less absenteeism, higher
productivity, and lower healthcare expenses, which could
offset the cost of the immunizations. Society benefits
from reduced influenza cases by avoiding disruption to
business and communities that occurs from either sea-
sonal or pandemic infections. While this model uses the
terminology of employee and employer, employer savings
could be applied to other payers such as health plans or
government payers such as Medicare due to the flexibil-
ity of variables. Likewise, savings apportioned to employ-
ees could equally accrue to members of a health plan.
Because the cost of delivering vaccinations (and asso-
ciated cost sharing) differs by channel, the savings model
was developed to allow users to compare different deliv-
ery channels. Therefore, the objective of this research
was to compare cost benefit of various immunization




The cost benefit model was designed to evaluate the
costs, benefits, and net savings associated with influenza
immunizations. It is used to illustrate the financial value
of a program to a set of stakeholders over a specific time
period. Sensitivity testing is performed to vary the user
input and model assumptions to make sure the best
model assumptions are used to generate the most rea-
sonable the financial value projections. We used an actu-
arial approach because it allows for multiple interrelated
assumptions around various aspects of risks for a set of
contingent future events to determine the most reason-
able time value of money for different stakeholders [14].
The model provides users with a base set of assumptions
and variable values derived from literature but with con-
siderable ability to vary those assumptions interactively
for specific populations. Key variables that affect outcomes
are summarized in Table 1 and organized into inputs, costt Categories Outputs
ospitalization • Number of members immunized
utpatient visits • Expected cost of immunizations
lf-medication • Expected saving total
bsenteeism • Stakeholder allocation
esenteeism • Expected net saving total
eath • Expected net savings per vaccinated (PV) member
• Expected net saving per member per year (PMPY)
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were taken from two studies: Molinari et al. [1] and Pros-
ser et al. [12]. Both studies used Monte Carlo simulations
based on the same retrospective analysis of influenza-
related utilization over multiple years from a large data-
base of insurance claims (Medstat Marketscan) to model
costs of influenza.
Molinari et al. first used national epidemiological data
and published studies to estimate the probability of four
categories of influenza health outcomes: illness, out-
patient visits, hospitalizations, and death. All probabil-
ities were age and risk stratified. Next, Molinari and
colleagues estimated direct and indirect costs associated
with influenza. Most direct costs were based on 179,718
cases of influenza identified in the Medstat Marketscan
database between 2000 and 2004. Indirect costs valued
lost productivity due to illness or death. Monte Carlo
simulations with sensitivity analysis yielded estimated
cases and average costs (with 95% upper and lower con-
fidence intervals). The probabilistic model predicted an
estimated 30,151,934 annual cases that resulted in 21,354
[22,636, 43,507] outpatient visits, 3,131 [2,108, 4,511] in-
patient days, 44,003 [25,694, 62,484] lost productivity
days, and 611 [360, 953] undiscounted life years lost.
Total direct costs and total economic burden in 2003
dollars was estimated as $10.4 billion [$4.1, $22.2] and
$87.1 billion [$47.2, $149.5], respectively.
Molinari et al. did not project potential savings for
averted cases due to vaccination; however, Prosser et al.
built on Molinari’s cost assumptions to estimate cost sav-
ings of vaccination in various clinical settings, such as
mass vaccination events, pharmacy and doctors’ offices.
Prosser et al. noted that non-traditional settings, such as
pharmacies, were highly cost effective. While their results
provided general guidance for comparative cost efficacy,
estimating cost efficacy for a particular population would
require some effort. Hence, we built upon the foundation
of both previous studies to build a decision support tool
to model various immunization strategies.
Inputs
1. Projection Year: Because of medical inflation, cost
variables will differ by calendar year. The underlying
assumptions and factors in the model are derived
from different years and inflation factors are used to
adjust the literature-based variables to project to the
period chosen by the model user. Medical costs were
adjusted by medical trend, while non-medical costs
were adjusted by the consumer price index. The
default projection year is the next
(i.e., upcoming) influenza season.
2. Population demographics: Risk of influenza and its
complications varies by age. While some populations(e.g., employers) will be more heavily weighted
towards younger persons as employers terminate
their retiree benefits, other populations such as a
Medicare health plans may be older. Therefore, the
model allows users to tailor savings estimates to the
specific demographics of the client population. Five
age groupings are used in the model: ≤11 (children),
12–17 (youth), 18–49 (young adults), 50–64
(middle-age adults), and 65 and older (older adults).
A sample population of 15,000 persons is provided
as a default in the model with a typical age profile
(13%, 13%, 40%, 20%, and 13%, by respective age
group), based on a 2009 estimate of the U.S. census
[15].
3. Vaccination delivery channel: By surveying non-
traditional immunization providers, Prosser et al.
[12] found that the immunization costs were lower
at mass vaccination events and pharmacies
compared to traditional channel (TC) settings. To
compare costs across channels, three input variables
were needed: cost in traditional settings ($TC), cost
in non-traditional settings ($NTC), and the
proportion of persons using non-traditional channels
(%NTC). To provide a default value for traditional
channels, we derived an average allowed charge per
physician administered influenza vaccination
($TC = $82) from a large national dataset
[Unpublished data from Solucia Consulting's
proprietary database]. The model also allows users to
adjust the expected utilization of non-traditional
settings (default %NTC = 0.50) and the cost of
immunizations in such settings (default $NTC = $30).
4. Percent vaccinated: As evidenced in the literature,
not everyone who should get a flu shot actually gets
one [16]. Coverage rates not only remain below
national targets but also vary substantially by age
group. To account for this variation, the model
permits users to estimate the percent of population
who are successfully vaccinated by age group. The
model provides default coverage rates by age group
(< 11: 55.2%, 12–17: 55.2%, 18–49: 49%, 50–64: 49%,
65+: 72%) based on U.S. coverage during the 2009/
2010 season [16]. Alternatively, users can enter their
own projected coverage distribution. Of note, this
measure of adherence is distinct from vaccine
effectiveness, which is discussed later in this
section.
5. Economic assumptions: Economic assumptions
include productivity and wages. The model provides
baseline numbers based on U.S. averages [15], but
allows the user to vary these assumptions to meet
the needs of a specific population. To increase
precision of productivity and death cost estimates,
three inputs are required to calculate the average
Duncan et al. Cost Effectiveness and Resource Allocation 2012, 10:10 Page 4 of 11
http://www.resource-allocation.com/content/10/1/10value of a lost workday: (a) Current Average Annual
Wage, (b) Ratio of Benefits to Wages, and (c)
Assumed Workdays per Year. The default
assumption is an average annual salary of $40,000
with a 250 workday year increased by 30% to
accommodate the value of employee benefits.
6. Benefit design: By providing details of cost sharing of
vaccination and other medical services, the model is
able to allocate costs and benefits to employers and
employees. The default values assume that the plan
(as funded by the employer) covers 90% of the
vaccination costs and 78% of general medical costs
[17]. When the benefit design for a particular
population is known and different from the default
value, the model can more accurately portray the
distribution of cost and savings estimates to
stakeholders.
7. Preventable cases: The proportion of ILI cases that
can be prevented by vaccination is contingent on the
effectiveness of vaccine and the incidence of disease.
Effectiveness of the seasonal influenza vaccine varies
by year, depending on many factors including the
infectivity, pathogenicity, and virulence of the viral
strains and the antigenic match with the vaccine.
Furthermore, effectiveness varies by age group (due
to human behaviors and social networks as much as
characteristics of the virus) or co-morbid risk factors
(due to decreased immunity). Interconnected with
effectiveness, incidence also varies by strain and by
age group. Two published studies [12,18] combined
these concepts of vaccine effectiveness and influenza
incidence into a rate of avoidable cases that was used
in our model. The proportion of avoidable cases was
higher in children aged 5–11 (5.5%) and persons
aged 65 and older (5.4%) compared to youth aged
12–17 years (4.1%), young adults aged 18–49 years
(4.6%), or middle-aged adults 50–64 (4.6%). For our
model, estimated avoided cases among children
under 5 years were assumed to be similar to children
aged 5–11. These figures were based on non-
pandemic years. To account for greater infectivity
and severity during pandemic years, the model
incorporates a pandemic risk factor, which is
discussed in a later section.
8. Risk Level: Individuals at higher risk for ILI and its
complications are more likely to incur ILI-related
expenses compared with individuals with lower risk.
Several published studies stratified cost assumptions
by risk category. Therefore, the model allows one of
two immunization strategies based on risk level:
(a) immunizing the entire population (i.e., universal
vaccination) or (b) targeting at-risk individuals. The
definition of high risk followed Molinari et al. [1],
who defined high risk as the presence of at least oneco-morbid condition, as listed in Advisory
Committee on Immunization Practices (ACIP)
guidelines [4]. The risk profile by Molinari et al.
estimated the proportion of high-risk individuals
among age 17 and under, aged 18–49 years, 50–64
years, and 65 and older as 10.6%, 14.9%, 33.0%, and
51.2%, respectively. Although the Molinari profile
was published between 1994 and 1997, this
distribution was used because it remains consistent
with 2010 CDC reported risk strata: 8.6% of youth
(aged 12–17 years), 15.2% of young adults (aged
18–49 years), and 33.5% of middle-aged adults
(aged 50–64 years). To be consistent with
current ACIP guidelines, our model assumed all
persons aged 65 and older were considered at
high risk of influenza infection and complications
[4]. The difference between a population and
high-risk strategy is the type of individuals
targeted for vaccination. Such strategies do not
assume that all targeted individuals received the
vaccination; therefore, coverage rates were also
applied to high-risk vaccination programs.
9. Risk of Pandemic: During years with pandemic
influenza, the value of vaccination is greater because
the risk of exposure and infection is higher
compared to non-pandemic years [13]. Based on the
available data from the last three pandemics, Crowe
and colleagues [19] estimated that there is a 2%
probability of a pandemic (PrP = .02) in any given
year, and pandemic flu incidence ranged from 9% to
35% , compared to 4% to 6% in non-pandemic years.
Since incidence of pandemic influenza continues to
vary with age, an attack rate adjustment (ARA) was
used to tailor risk for the age distribution in the
model:
ARA ¼ pandemic incidence=age
 weighted average
non-pandemic incidence
To account for the potential of a pandemic in any
given year, utilization costs were adjusted by a pandemic
risk adjustment factor (PRA), whereby:
PRA ¼ 1 PrPð Þ * 1þ PrP * ARA
Cost categories
Influenza and its complications impose costs on patients,
health plans, employers, and society. The literature iden-
tified six categories of potential costs associated with a
diagnosis of influenza: inpatient hospitalization, out-
patient visits, self-medication, death, and productivity
(presenteeism and absenteeism).
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the hospitalization episode to include inpatient costs
as well as outpatient and pharmacy services incurred
2 weeks prior and 4 weeks after the inpatient stay.
Using Molinari’s definition, Prosser et al. reported
hospitalization costs by age and risk. For example,
among persons without risk factors for influenza,
hospitalization was most costly for persons who
were aged 50–64 years (Mean = $23,281; Range:
$20,887-$26,159) [12]. This model used Prosser’s
2004 mean estimates, which were trend adjusted for
the projected program year.
2. Outpatient visits: As one of the most frequent costs
of influenza, outpatient services were defined by
Molinari et al. as visits to primary care providers,
specialists, urgent care clinics, and emergency rooms
for an ILI. In addition to the cost of the visit, any
pharmacy and laboratory services within a 3-day
window were also included to estimate total
outpatient costs not associated with inpatient
episodes. Like hospitalizations, the range of
outpatient costs were age and risk dependent
(range = $51-$765 per person with
influenza) [12,18].
3. Self-medication: Use of over-the-counter (OTC)
medications is an early indicator of disease because
many patients will use OTC either in lieu of or in
addition to seeking medical care [20]. The cost of
the typical "flu basket" was used to provide an
approximation of the costs of self-medication. The
flu basket includes products that are sold along with
purchase of an OTC flu medicine, such as cough
drops, pain relievers, decongestants, or juice. A
retrospective analysis of data from a large pharmacy
chain was used to estimate the average value of the
basket in 2010.
4. Death: In the model, the costs associated with death
were based on the value of a statistical life (VSL),
which is a commonly used and comprehensive
estimate to represent the “lost productivity as well as
the intrinsic, or social, value place on human life”
[1]. To calculate the savings from death avoided
due to influenza vaccination, costs associated with
death (as reported by Spurr in Molinari et al.) [1]
were multiplied by the proportion of preventable
deaths (as reported by Grosse in Prosser et al.)
[12,18].
5. Absenteeism and presenteeism: In the United States,
presenteeism and absenteeism due to influenza
accounts for approximately 17 million lost workdays
per year [21].
a. Absenteeism is defined as days taken off work to
care for influenza illness in oneself, a child, orother dependent. In the Molinari study [1],
estimated lost workdays ranged from 0.5-1.0 days
in non-treated ILI, 1–7 days in outpatient-treated
ILI, or 8–24 days in ILI requiring hospitalization.
Absenteeism due to child’s illness ranged from
0.7-2.8 days per episode of flu. While this latter
estimate seemed low, the estimate may be
reasonable given that only one parent in a two-
parent household would take time off.
b. Presenteeism was defined as decreased
productivity due to workers with influenza
continuing to be present in the workplace [22].
Presenteeism was estimated from the average
reduced work effectiveness days as reported by
Nichol [23].Estimated days lost due to either absenteeism or pres-
enteeism was transformed into costs by multiplying by
the calculated average daily wage of the population, as
discussed in the previous input section.
Model outputs
Our basic cost model estimates net savings as total costs
avoided due to disease prevention from vaccination
minus the total costs of vaccination. This calculation is
comparable to that reported by Nichol et al. [23] but
provides cost output as a positive savings rather than
negative costs.
1. Number of persons immunized (NPI) was calculated
from the input number of individuals in the
population in an age category, multiplied by the
expected coverage in each age category, and totaled
across all age categories. As previously discussed, the
default vaccination rates are based on national
coverage estimates by age. When a high-risk strategy
is selected (HR= 1), NPI also accounts for the
proportion of individuals who were estimated to be
high risk by age group. Therefore:
NPI ¼ Σ ni * Við Þ * if HR ¼ 1;HRið Þ; 1Þ;
where n= subset of persons in the ith age category,
with the corresponding estimates of coverage (Vi)
and high risk (HRi).
2. Expected total immunization cost (COSTS) for a
non-traditional channel (NTC) such as pharmacies
and a traditional channel (TC) such as doctor’s
offices were calculated as a product of the unit cost
of vaccination ($) in that channel multiplied by the
count of number of persons vaccinated in
each channel. Therefore, total costs were estimated
as:
$NTC  nNTCð Þ þ $TC  1 nNTCð Þð Þ;
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non-traditional channels.
These assumptions were discussed in the input
section (3).
3. Total expected savings (SAVINGS) from avoided
influenza cases are derived, for each risk and age
category, from the product of (a) the number of
persons immunized, (b) the estimated preventable
cases per person immunized, (c) the unit of
utilization per preventable case for each cost
category, and (d) the unit cost for each cost
category. For example, the equation for savings from
avoided inpatient (IP) utilization is:
SAVING IPð Þ ¼ NPI Preventable flu casesð Þ
Person immunizedð Þ 
IP
Flu case
 Average flu IP cost
Parallel equations were constructed for outpatient,
medication, and productivity savings. Total savings
was the sum of these potential savings, in addition to
estimated savings from averted deaths, which is
discussed in the next section.
4. Stakeholder allocation: In the model, vaccination
cost and savings are allocated to three stakeholders:
payers (e.g., employers, health plans, or government
payers), individuals (e.g., health plan members or
employees and their dependents), and society (e.g.,
communities, families).
a. Total costs of vaccination were distributed to
employers or employees based on the proportion
of immunization cost sharing (‘Vaccination
Cost Sharing % by Employers’). No costs
associated with vaccination were allocated to
society.
b. All savings from self-medication costs were
allocated solely to the employee.
c. Depending on how labor is compensated, the cost
of sick time may be borne by the employer as
reduced productivity, passed to the employee
through reduced wages (as in the case of hourly-
paid workers), or passed to an insurer (when
absence is insured, for example with short-term
disability). In this model, savings from avoided
absenteeism was applied to the employer category.
d. All savings from presenteeism are credited to
employers.
e. Savings from avoided outpatient and inpatient
events are split between employers and members,
based on the benefit plan design.
f. The cost savings from avoided death were shared
by all three stakeholders. Of the total VSL,approximately 75% was allocated towards societal
savings, whereas the remaining 25% was
apportioned to employers and employees. For
employer groups particularly, a number of
members will be dependents or could be retirees.
Therefore, savings from avoided death was
applied only to the members who were also
employees. Therefore, this allocation is dynamic
and based on enrollment input. The model
assumes that 40% of members were employees,
although this proportion could be adjusted.
Employers were allotted savings equal to the
product of (a) twice the annual salary (SAL) of
an employee, (b) the proportion of the
population who were employees, and (c) the age-
weighted count of preventable deaths. This figure
accounts for the loss productivity in an
employee’s role until a new employee is hired
and fully trained. For an employee, or rather, for
the family of an employee, the loss of life
accounts for projected loss of future earnings as
well as the value to the family unit. This amount
was allocated as estimated VSL multiplied by the
percent of VSL that was allocated to the present
value of future earnings (% PVFE) minus the
employer’s portion. The remaining portion of the
VSL reflected loss of the intrinsic value of life to
society. The equations for each of these
portions are:
Employer= age-weighted unit preventable
death * 2 * SAL * % members employed
Employee= ($VSL * % PVFE) – Employer
Society= $VSL – Employer’s portion –
Employee portion
Aggregate cost and savings estimates across all
stakeholders, as well as an aggregate of employer
(payer) and employees (members) savings are
provided.
5. Expected net savings equaled total SAVINGS – total
COSTS (i.e., 3–2).
6. Expected net savings per vaccination (PV) was the
net savings total divided by the number of persons
immunized (i.e., 5 / 1).
7. Expected net saving per member per year (PMPY)
was the net savings total divided by the number of
enrolled members.
Results
Five immunization scenarios were run for a fictitious
company with 15,000 members and compared with a
baseline (See Figure 1). As shown in the second column
Figure 1 Output from model comparing immunization strategies. Note. WAG = immunization at Walgreens.
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tion strategy (i.e., not high-risk) where 50% of indivi-
duals are vaccinated at pharmacies rather than a
physician office. This strategy assumed vaccination of
employees as well as their spouses and children. This
baseline was compared to five possible immunization
strategies:
1. Employee population only (i.e., not including
dependents).
2. Full population vaccination with 100% at pharmacies
3. High risk individuals targeted with 50% at
pharmacies.
4. High-risk individuals targeted with 100% vaccination
at pharmacies.
5. Vaccination of seniors (65+) with 50% at
pharmacies.
As described in the demographics assumption, the ma-
jority of population (60%) in the baseline scenario was
assumed to be adults aged 18 to 64 years, with relativelyfew aged 65 and older (13%) and fewer than one in four
under age 18 (26%). Assuming national age-specific
coverage, 8,034 of 15,000 (54%) of individuals would be
vaccinated.
Figure 1 presents the results of the baseline and other
scenarios from the perspective of payers (Client ABC),
members, society, and total (payer & member & society).
The baseline model demonstrated that vaccinating all
individuals in the sample population was cost effective
from a payer perspective (expected net saving $6 PV; $3
PMPY) as well as from a member ($47 PV; $25 PMPY)
and societal perspective ($154 PV; $82 PMPY). Total ex-
pect net savings to all stakeholder was estimated at $207
per vaccination.
Targeting employees (i.e., adults only) with at least 50%
of employees being immunized at a pharmacy derived an
employer cost savings of $49 per vaccination, compared
to the baseline estimate of $6 per vaccination.
Increasing the proportion of vaccinations in pharma-
cies compared to PCP offices, increased the cost savings,
as demonstrated by comparing the baseline and second
Duncan et al. Cost Effectiveness and Resource Allocation 2012, 10:10 Page 8 of 11
http://www.resource-allocation.com/content/10/1/10scenarios in Figure 1. If the proportion of pharmacy-
based immunizations is increased from 50% to 100%, the
expected net savings for employers increased net savings
per vaccination from $6 to $31.
Specifically targeting only high-risk individuals resulted
in similar cost savings to pharmacy-based vaccination.
Cost savings for employers was estimated to be $83 per
vaccination for an at-risk strategy, compared to of $6 per
vaccination for the population-strategy baseline. Cost
savings were maximized by both targeting high-risk indi-
viduals and increasing the proportion of vaccination at
pharmacies. When at-risk members were targeted and
100% of vaccinations occur in pharmacies, expected net
savings increased to $108 per vaccination.
Individuals aged 65 and older represent a segment of
persons deemed especially high risk by the CDC [16]. If
framed from a health plan prospective, such as a Medi-
care Advantage (managed care) plan or retiree benefits
plan, the expected net savings from immunizing 15,000
seniors yielded $107 per person vaccinated.
Confirming the findings from comparing scenarios,
sensitivity analysis demonstrated that expected net sav-
ings for employers was most influenced by changes in
age distribution of the target population (Range PMPY=
[$-4.03, $106.94]), targeting at-risk populations ([$6.47,
$83.46]), and the percent of vaccination in non-
traditional settings [$-17.92, $30.87]). Results from the
full sensitivity analysis are provided in Table 2. Of note,
positive net saving (PMPY= $2.83) was estimated even if
the model assumed no risk of pandemic.
Figure 2 shows the change in employer savings that
occurs when a larger share of the vaccinations are at
pharmacies. When more than 37% of vaccinations were
given at non-traditional, low cost settings, such as phar-
macies, employers realized positive savings. AllTable 2 Sensitivity analysis of employer expected net savings
Variable Baseline Sc
Client Population Demographic U.S. Average
Risk level (Targeting High Risk) No
Vaccination Channel:% in NTC 50%
Salary (Economic Variable) $40 K
Expected Cost of Immunization in TC $82
% Vaccine Cost Covered by Plan 90%
Expected Cost of Immunization: NTC-TC extremes $28:$82
% General Medical Cost Covered by Plan (Benefit Design) 78%
Expected Cost of Immunization: NTC $28
Risk of Pandemic ~2%
Ratio Benefit to Wage (Benefit Design) 30%
Projection Year 2012
Average Percentage Vaccinated ~54%
Notes. NTC =non-traditional channel; TC = traditional channel.alternative strategies were more cost beneficial than
baseline. The slope of cost benefit increases with the
number of vaccinated persons, which causes the effect of
decreasing vaccination to be more valuable in larger
populations.
Discussion
Synopsis of key findings
 This comprehensive model incorporated multiple
sources of costs and benefits and allowed users to
customize an immunization strategy according to
the characteristics of the population. Depending on
population, a broad immunization strategy was not
always economically justified.
 To evaluate the costs and benefits of offering
vaccinations in alternative settings, vaccination in
pharmacies were compared to the traditional
vaccination setting of a primary care doctor’s office.
Increasing the proportion of vaccination at
pharmacies proportionally increased the cost savings
of a modeled influenza immunization program. The
primary mechanism for this savings was the
elimination of the cost of an outpatient visit for the
proportion of immunizations performed in a doctor’s
office.
 Compared to the baseline model, the ability to reach
and vaccinate high-risk individuals increased cost
savings. Likewise, immunizing seniors increased cost
savings. A major driver of cost savings in these
scenarios was avoiding serious complications, such
as hospitalization and death, which are more
prevalent in at-risk populations.
 An important finding of this research was that
universal immunization of an average U.S.(ENS) per member per year (PMPY)
enario Input Range Output Range
[No children/seniors, Seniors only ] [$-4.03, $106.94]
[No, Yes] [$6.47, $83.46]
[0%, 100%] [$-17.92, $30.87]
[$30 K, $60 K] [$-1.69, $22.82]
[$60, $100] [$16.48, $-1.52]
[80%, 100%] [$11.99, $0.97]
[$23:$100, $41:$60] [$0.72, $10.63]
[60%, 90%] [$1.07, $10.08]
[$23, $41] [$8.73, $0.62]
[0%, 4%] [$2.83, $10.14]
[20%, 40%] [$4.21, $8.75]
[2011, 2013] [$4.17, $8.92]
[~44%, ~64%] [$7.67, $5.69]
Figure 2 Opportunity analysis.
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perspective as long as 30% of vaccinations occur at
low-cost, non-traditional settings such as
pharmacies.
 Furthermore, universal vaccination produced
substantial cost savings from individual and societal
perspectives.
Comparison to relevant published work
The foundation of the model is a body of evidence-based
assumptions from the published health literature. As
expected, our results were consistent with findings from
studies we used for our assumptions, such as Prosser
et al. [12] and Molinari et al. [1]. For example, like Pros-
ser et al., our model found that non-traditional setting
increased cost savings for older and high-risk popula-
tions. However, a significant advantage of our model is
the ability to actuarially adjust assumptions to fit
requirements of different populations and to project to
future years.
Based on the Behavioral Risk Factor Surveillance Sys-
tem 2010–11 survey, retail stores (including pharmacies)
and workplaces provided 18.4% and 17.4% of influenza
vaccinations, respectively [24]. On the other hand, doc-
tors' offices provided 39.8% of vaccination. Assuming the
results of this model are correct, opportunity exists for
improving cost benefit of vaccination programs.
Although focused on workplace vaccinations, Lee et al.
[13,25] developed a decision model for the value of for
employers and found that, depending on the serologic at-
tack rate, cost-savings varied from $15-$995 to $39-
$1,494 per vaccinated employee. Lee et al. focused moreon the importance of immunizing employees as a com-
ponent of pandemic planning, and thus used higher esti-
mates of influenza incidence (15% – 25%) compared
with our default range (4.1% – 5.5%). Using the default
parameters, our model is conservative from an employer
cost perspective, providing a maximum savings estimate
of $108 per vaccination for high-risk persons at pharma-
cies. Unlike our model, Lee et al. allocated all savings to
employers rather than allocating any savings to society
or employees. In fact, most of the published literature
did not report costs and savings by various stakeholders.
Bowen et al. [26] developed an online model of cost sav-
ings for preventive services, though not specific to influ-
enza vaccination and only from the patient perspective.
Our results also echo those by Rothberg and Rose [27]
who found that vaccination of working adults was cost
saving under certain circumstances. Rather than compar-
ing channels, Rothberg and Rose compared vaccination
and anti-viral treatment to no treatment. In their model,
lower vaccination cost or more than 2.4 days off work
made vaccination more cost effective than the alterna-
tives. Although our model did not consider anti-viral
treatment, both models support immunization of work-
ing adults. Earlier research by Akazawa, Sindelar, and
Paltiel [28] did not find vaccination of working-age indi-
viduals to be cost effective; however, as medical costs in-
crease, avoiding illness and its related costs increasingly
outweighs cost of preventive measures such as
immunization. A 2001 model by Nichol [23] estimated a
net savings of $13.66 (95% CI: -2.18, 32.97) per vacci-
nated person among health working adults. Similar to
our results, a 2006 model by Maciosek and colleagues
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under age 65 was reasonably cost effective and immuniz-
ing adults age 65 and above was highly cost effective.
Limitations of the model
Although the model incorporates a comprehensive set of
variables that affect cost benefit of vaccination, the
current model did not account for possible interactions
between such variables [30]. Many assumptions were
based on two Monte Carlo models in the published lit-
erature. Both of these models were based on the same
retrospective cohort of medical claims in the mid-
Atlantic U.S., and therefore, extrapolation to populations
that vary significantly from this cohort would not be
advised.
Although the use of value of the statistical life (VSL) is
a standardized measure from the literature, VSL limited
the ability of the model to adjust the costs of death to
the average salary of the population. Absenteeism and
presenteeism did not account for the possibility of ex-
empt employees working extra hours later rather than
losing compensation (i.e., using sick day).
Not all variables that influence cost benefit could be
accounted for in the model. As discussed, our model did
not compare immunization versus antiviral therapy. This
model did not take into account the timing of vaccin-
ation within the season. For example, previous research
[8] found that October was the most cost effective
month to vaccinate older persons. In fact, delaying vac-
cination by even one month was estimated to increase
both societal (by $400-490/1,000 persons) and third
party payer costs (by $330-500/1,000 persons). However,
they also found that vaccination up until February was
still cost-effective. Therefore, vaccine interventions
should strive to achieve the majority of vaccinations as
soon as seasonal influenza vaccine is available and at
least before February of a given influenza season.
Implications for future research
Few articles were found that tested the accuracy of pre-
dictive outcomes of influenza vaccination cost models in
actual practice. A recent Italian survey by Garattini and
Koleva [31] demonstrated that vaccinated workers were
less likely to be absent due to ILI, and thus validated this
outcome of their model. While these findings from Italy
are encouraging, validation of this model’s assumptions
or outcomes in an U.S. employer group would
strengthen support for its application.
Conclusions
This paper described the development of an actuarial
model to articulate the economic value of seasonal influ-
enza vaccinations from various perspectives. Given the
recent H1N1 pandemic, there is increasing awareness ofthe need for pandemic planning even in the private sec-
tor. The overriding objectives of the U.S. pandemic plan
are “(1) limiting the burden of disease (i.e., morbidity
and mortality); (2) minimizing social disruption caused
by the pandemic; and (3) reducing economic losses at-
tributable to the pandemic” [32]. Companies can support
these goals by maximizing benefit of their immunization
programs. This model can be used to help employers or
health plans understand the impact of flu and vaccina-
tions within their population. Furthermore, this decision
model could provide policy makers with evidence-based
value to compare immunization strategies and salient
outcomes. Comparing various vaccination scenarios in
this model confirms that targeting high-risk populations
improves cost benefit of vaccination programs. More-
over, the model demonstrates that universal vaccination
can be cost beneficial, especially when immunizations
are provided in non-traditional settings such as
pharmacies.
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